{"title":"18F-florbetapir PET两种临床Centiloid分析产品在认知功能未受损老年人中的评价。","authors":"Frank P DiFilippo, Stephen M Rao","doi":"10.1002/dad2.70163","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Recently two software products (MIMneuro and Syngo.PET) received United States Food and Drug Administration (FDA) clearance for Centiloid analysis, thereby introducing Centiloid scoring to the clinical environment. This study compares Centiloid scores by these clinical products and conventional research methods.</p><p><strong>Methods: </strong><sup>18</sup>F-Florbetapir amyloid positron emission tomography (PET) scans (<i>N </i>= 252) of cognitively unimpaired elders were processed using both products and using research pipelines based on the Standard Centiloid method (magnetic resonance imaging [MRI]-based spatial normalization).</p><p><strong>Results: </strong>Centiloid scores from both products were highly linearly correlated with each other (<i>r<sup>2 </sup></i> = 0.942) and with an MRI-based research pipeline having matching regions of interest (MIMneuro: <i>r<sup>2 </sup></i> = 0.942, Syngo.PET: <i>r<sup>2 </sup></i> = 0.971). However, Centiloid scores often differed by more than 10 Centiloids [CL] between methods, with Centiloid calibrations contributing to their inconsistency.</p><p><strong>Discussion: </strong>Although Centiloid analyses were highly correlated, there was considerable variability in individual cases. Other factors not investigated (e.g., radiopharmaceutical, uptake time) could further contribute to variability. Clinicians should use caution when considering thresholds for amyloid positivity in individual cases.</p><p><strong>Highlights: </strong>Two newly available clinical software products, which provide rapid and simple Centiloid scoring, are compared to research processing involving both PET and MRI images.Excellent linear correlations were found among the methods.Centiloid scores for individual cases often differed by more than 10CL, which should be taken into consideration in clinical reporting.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70163"},"PeriodicalIF":4.4000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340231/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of two clinical Centiloid analysis products for <sup>18</sup>F-florbetapir PET in cognitively unimpaired elders.\",\"authors\":\"Frank P DiFilippo, Stephen M Rao\",\"doi\":\"10.1002/dad2.70163\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Recently two software products (MIMneuro and Syngo.PET) received United States Food and Drug Administration (FDA) clearance for Centiloid analysis, thereby introducing Centiloid scoring to the clinical environment. This study compares Centiloid scores by these clinical products and conventional research methods.</p><p><strong>Methods: </strong><sup>18</sup>F-Florbetapir amyloid positron emission tomography (PET) scans (<i>N </i>= 252) of cognitively unimpaired elders were processed using both products and using research pipelines based on the Standard Centiloid method (magnetic resonance imaging [MRI]-based spatial normalization).</p><p><strong>Results: </strong>Centiloid scores from both products were highly linearly correlated with each other (<i>r<sup>2 </sup></i> = 0.942) and with an MRI-based research pipeline having matching regions of interest (MIMneuro: <i>r<sup>2 </sup></i> = 0.942, Syngo.PET: <i>r<sup>2 </sup></i> = 0.971). However, Centiloid scores often differed by more than 10 Centiloids [CL] between methods, with Centiloid calibrations contributing to their inconsistency.</p><p><strong>Discussion: </strong>Although Centiloid analyses were highly correlated, there was considerable variability in individual cases. Other factors not investigated (e.g., radiopharmaceutical, uptake time) could further contribute to variability. Clinicians should use caution when considering thresholds for amyloid positivity in individual cases.</p><p><strong>Highlights: </strong>Two newly available clinical software products, which provide rapid and simple Centiloid scoring, are compared to research processing involving both PET and MRI images.Excellent linear correlations were found among the methods.Centiloid scores for individual cases often differed by more than 10CL, which should be taken into consideration in clinical reporting.</p>\",\"PeriodicalId\":53226,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"volume\":\"17 3\",\"pages\":\"e70163\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340231/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/dad2.70163\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70163","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Evaluation of two clinical Centiloid analysis products for 18F-florbetapir PET in cognitively unimpaired elders.
Introduction: Recently two software products (MIMneuro and Syngo.PET) received United States Food and Drug Administration (FDA) clearance for Centiloid analysis, thereby introducing Centiloid scoring to the clinical environment. This study compares Centiloid scores by these clinical products and conventional research methods.
Methods: 18F-Florbetapir amyloid positron emission tomography (PET) scans (N = 252) of cognitively unimpaired elders were processed using both products and using research pipelines based on the Standard Centiloid method (magnetic resonance imaging [MRI]-based spatial normalization).
Results: Centiloid scores from both products were highly linearly correlated with each other (r2 = 0.942) and with an MRI-based research pipeline having matching regions of interest (MIMneuro: r2 = 0.942, Syngo.PET: r2 = 0.971). However, Centiloid scores often differed by more than 10 Centiloids [CL] between methods, with Centiloid calibrations contributing to their inconsistency.
Discussion: Although Centiloid analyses were highly correlated, there was considerable variability in individual cases. Other factors not investigated (e.g., radiopharmaceutical, uptake time) could further contribute to variability. Clinicians should use caution when considering thresholds for amyloid positivity in individual cases.
Highlights: Two newly available clinical software products, which provide rapid and simple Centiloid scoring, are compared to research processing involving both PET and MRI images.Excellent linear correlations were found among the methods.Centiloid scores for individual cases often differed by more than 10CL, which should be taken into consideration in clinical reporting.
期刊介绍：
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
